{"classes":[{"categories":[{"measurements":[{"comment":"A confidence interval cannot be estimated at this time-point because no one had lost response.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"1.00"}]}],"title":"16 weeks"},{"categories":[{"measurements":[{"comment":"A confidence interval cannot be estimated at this time-point because no one had lost response.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"1.00"}]}],"title":"32 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.72","upperLimit":"0.98","value":"0.92"}]}],"title":"48 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.72","upperLimit":"0.98","value":"0.92"}]}],"title":"64 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.72","upperLimit":"0.98","value":"0.92"}]}],"title":"80 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.67","upperLimit":"0.96","value":"0.88"}]}],"title":"96 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.62","upperLimit":"0.94","value":"0.84"}]}],"title":"112 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.62","upperLimit":"0.94","value":"0.84"}]}],"title":"128 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.62","upperLimit":"0.94","value":"0.84"}]}],"title":"144 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.57","upperLimit":"0.91","value":"0.79"}]}],"title":"160 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.57","upperLimit":"0.91","value":"0.79"}]}],"title":"176 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.51","upperLimit":"0.88","value":"0.74"}]}],"title":"192 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.51","upperLimit":"0.88","value":"0.74"}]}],"title":"208 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.51","upperLimit":"0.88","value":"0.74"}]}],"title":"224 weeks"},{"categories":[{"measurements":[{"comment":"No additional progression was experienced within population at week 240.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"240 weeks"},{"categories":[{"measurements":[{"comment":"No additional progression was experienced within population at week 256.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"256 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"description":"Duration of the primary response is defined as the time from the first occurrence when both components of the primary endpoint are met until the date of the first documented disease progression (end of response).\n\nKaplan-Meier estimates are provided for duration of primary response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy","id":"OG000","title":"Ruxolitinib"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS) comprises all participants to whom study treatment had been assigned by randomization. Duration of response was pre-specified in the protocol to be analyzed for the ruxolitinib arm only considering the study design which allowed crossover for the BAT arm beginning at Week 32.","reportingStatus":"POSTED","timeFrame":"Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study","title":"Estimated Duration of the Primary Response","type":"SECONDARY","unitOfMeasure":"probability"}